Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Obesity and cardiovascular disease.

Apovian CM, Gokce N.

Circulation. 2012 Mar 6;125(9):1178-82. doi: 10.1161/CIRCULATIONAHA.111.022541. No abstract available.

2.

Letter by hendricks regarding article, "obesity and cardiovascular disease".

Hendricks EJ.

Circulation. 2012 Sep 18;126(12):e191; author reply e192. doi: 10.1161/CIRCULATIONAHA.112.115444. No abstract available.

3.

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH.

Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7.

4.

European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes.

Jordan J, Schlaich M, Redon J, Narkiewicz K, Luft FC, Grassi G, Dixon J, Lambert G, Engeli S; European Society of Hypertension Working Group on Obesity; Australian and New Zealand Obesity Society.

J Hypertens. 2011 Feb;29(2):189-93. doi: 10.1097/HJH.0b013e3283427c8b. Review. No abstract available.

PMID:
21178784
5.
6.

Phentermine and topiramate extended-release for the obesity: new kids on the block.

Katsi V, Marketou M, Kallistratos MS, Tousoulis D, Makris T, Manolis AJ, Vardas P, Kallikazaros I.

Recent Pat Cardiovasc Drug Discov. 2013 Apr;8(1):35-41. Review.

PMID:
23565717
7.

Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.

Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B.

Diabetes Care. 2014 Dec;37(12):3309-16. doi: 10.2337/dc14-0930. Epub 2014 Sep 23.

PMID:
25249652
8.

Drug treatment of obesity.

Smith SR.

JAMA Intern Med. 2014 Aug;174(8):1414-5. doi: 10.1001/jamainternmed.2014.1646. No abstract available.

PMID:
25090179
9.

Drug treatment of obesity.

Kyle TK, Nadglowski J Jr.

JAMA Intern Med. 2014 Aug;174(8):1414. doi: 10.1001/jamainternmed.2014.1640. No abstract available.

PMID:
25090178
10.

Drug treatment of obesity--reply.

Schwartz LM, Woloshin S.

JAMA Intern Med. 2014 Aug;174(8):1415-6. doi: 10.1001/jamainternmed.2014.1635. No abstract available.

PMID:
25090180
11.

Obesity and Type 2 diabetes; achieving weight loss.

Hitman GA, Finer S.

Diabet Med. 2011 Jun;28(6):627. doi: 10.1111/j.1464-5491.2011.03319.x. No abstract available.

PMID:
21569083
12.

Two anti-obesity hopefuls and their safety.

Bello NT, Campbell SC.

Expert Opin Drug Saf. 2012 Sep;11(5):681-3. doi: 10.1517/14740338.2012.706277. Epub 2012 Jul 13. No abstract available.

PMID:
22788876
13.

Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.

Walter CP, Bleske BE, Dorsch MP.

J Clin Pharm Ther. 2014 Oct;39(5):475-84. doi: 10.1111/jcpt.12177. Epub 2014 Jun 13. Review.

14.

Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.

Kelly EM, Tungol AA, Wesolowicz LA.

J Manag Care Pharm. 2013 Oct;19(8):642-54. Review.

15.

2 new drugs for weight loss.

[No authors listed]

Med Lett Drugs Ther. 2012 Sep 3;54(1398):69-71. No abstract available. Erratum in: Med Lett Drugs Ther. 2012 Sep 17;54(1399):76.

PMID:
22992487
16.

What cost weight loss?

Hiatt WR, Thomas A, Goldfine AB.

Circulation. 2012 Mar 6;125(9):1171-7. doi: 10.1161/CIRCULATIONAHA.111.023499. No abstract available.

17.

Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).

Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH.

Am J Cardiol. 2013 Apr 15;111(8):1131-8. doi: 10.1016/j.amjcard.2012.12.038. Epub 2013 Jan 29.

18.

Valvular heart disease with the use of fenfluramine-phentermine.

Surapaneni P, Vinales KL, Najib MQ, Chaliki HP.

Tex Heart Inst J. 2011;38(5):581-3.

19.

The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?

Woloshin S, Schwartz LM.

JAMA Intern Med. 2014 Apr;174(4):615-9. doi: 10.1001/jamainternmed.2013.14629.

PMID:
24515599
20.

Next generation of weight management medications: implications for diabetes and CVD risk.

Wharton S, Serodio KJ.

Curr Cardiol Rep. 2015 May;17(5):35. doi: 10.1007/s11886-015-0590-z. Review.

Supplemental Content

Support Center